GLORIOSA

Trial Description: 
Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRĪ±-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab
Lead Cooperative Group: 
Disease Site: 
Ovarian
Trial Status: 
Recruiting
Contact person: 
dlorusso